Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of SH-1028 with Itraconazole or Rifampicin in Healthy Men
NCT04808648Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 14, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 14 and 1 more. Status: unknown.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04808648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808648.